22 research outputs found

    A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.

    Get PDF
    Purpose Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory activities. This first-in-human phase I study (NCT01421524) evaluated the safety and clinical activity of avadomide in patients with advanced solid tumors, non-Hodgkin lymphoma (NHL), and multiple myeloma.Patients and methods Thirty-four patients were treated with avadomide in 7 dose-escalation cohorts using a 3 + 3 design (0.5-3.5 mg, 28-day continuous dosing cycles). The primary objectives were to determine the dose-limiting toxicity (DLT), nontolerated dose (NTD), maximum tolerated dose (MTD), recommended phase II dose, and pharmacokinetics of avadomide. The secondary objective was to determine preliminary avadomide efficacy. Exploratory objectives included evaluation of pharmacodynamic effects of avadomide.Results DLTs were reported in 2 patients, and grade ā‰„3 treatment-emergent adverse events (TEAEs) occurred in 14 patients (41%). The most common TEAEs (ā‰„15%) were fatigue, neutropenia, and diarrhea. The NTD and MTD were 3.5 and 3.0 mg, respectively. Of 5 patients with NHL, 1 achieved a complete response, and 2 had partial responses. Although no objective responses were observed in patients with solid tumors, 5 of 6 patients with brain cancer experienced nonprogression of ā‰„6 months. A dose-dependent relationship between Aiolos degradation in peripheral B and T cells occurred within 5 hours of the first dose of avadomide administered, starting at 0.5 mg.Conclusions Avadomide monotherapy demonstrated acceptable safety and favorable pharmacokinetics in patients with solid tumors, NHL, and multiple myeloma. In addition, 3 objective responses were observed in NHL

    Observation of a mu s isomer in In-134(49)85: Proton-neutron coupling "southeast" of Sn-132(50)82

    Get PDF
    We report on the observation of a microsecond isomeric state in the single-proton-hole, three-neutron-particle nucleus Ā¹Ā³ā“In. The nuclei of interest were produced by in-flight fission of a Ā²Ā³āøU beam at the Radioactive Isotope Beam Factory at RIKEN. The isomer depopulates through a Ī³ ray of energy 56.7(1) keV and with a half-life of T1/2=3.5(4)Ī¼s. Based on the comparison with shell-model calculations, we interpret the isomer as the IĻ€=5āˆ’ member of the Ļ€0gāˆ’19/2āŠ—Ī½1f37/2 multiplet, decaying to the IĻ€=7āˆ’ ground state with a reduced-transition probability of B(E2;5āˆ’ā†’7āˆ’)=0.53(6)W.u.Observation of this isomer, and lack of evidence in the current work for a IĻ€=5āˆ’ isomer decay in Ā¹Ā³Ā²In, provides a benchmark of the proton-neutron interaction in the region of the nuclear chart ā€œsoutheastā€ of Ā¹Ā³Ā²Sn, where experimental information on excited states is sparse

    Ī²-Delayed One and Two Neutron Emission Probabilities Southeast of ^{132}Sn and the Odd-Even Systematics in r-Process Nuclide Abundances.

    Get PDF
    The Ī²-delayed one- and two-neutron emission probabilities (P_{1n} and P_{2n}) of 20 neutron-rich nuclei with Nā‰„82 have been measured at the RIBF facility of the RIKEN Nishina Center. P_{1n} of ^{130,131}Ag, ^{133,134}Cd, ^{135,136}In, and ^{138,139}Sn were determined for the first time, and stringent upper limits were placed on P_{2n} for nearly all cases. Ī²-delayed two-neutron emission (Ī²2n) was unambiguously identified in ^{133}Cd and ^{135,136}In, and their P_{2n} were measured. Weak Ī²2n was also detected from ^{137,138}Sn. Our results highlight the effect of the N=82 and Z=50 shell closures on Ī²-delayed neutron emission probability and provide stringent benchmarks for newly developed macroscopic-microscopic and self-consistent global models with the inclusion of a statistical treatment of neutron and Ī³ emission. The impact of our measurements on r-process nucleosynthesis was studied in a neutron star merger scenario. Our P_{1n} and P_{2n} have a direct impact on the odd-even staggering of the final abundance, improving the agreement between calculated and observed Solar System abundances. The odd isotope fraction of Ba in r-process-enhanced (r-II) stars is also better reproduced using our new data

    <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Ī²</mml:mi></mml:math> -delayed neutron emissions from <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>N</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:math> gallium isotopes

    Get PDF
    Ī²-delayed Ī³-neutron spectroscopy has been performed on the decay of A=84 to 87 gallium isotopes at the RI-beam Factory at the RIKEN Nishina Center using a high-efficiency array of He3 neutron counters (BRIKEN). Ī²-2n-Ī³ events were measured in the decays of all of the four isotopes for the first time, which is direct evidence for populating the excited states of two-neutron daughter nuclei. Detailed decay schemes with the Ī³ branching ratios were obtained for these isotopes, and the neutron emission probabilities (Pxn) were updated from the previous study. Hauser-Feshbach statistical model calculations were performed to understand the experimental branching ratios. We found that the P1n and P2n values are sensitive to the nuclear level densities of 1n daughter nuclei and showed that the statistical model reproduced the P2n/P1n ratio better when experimental levels plus shell-model level densities fit by the Gilbert-Cameron formula were used as the level-density input. We also showed the neutron and Ī³ branching ratios are sensitive to the ground-state spin of the parent nucleus. Our statistical model analysis suggested Jā‰¤3 for the unknown ground-state spin of the odd-odd nucleus Ga86, from the IĪ³(4+ā†’2+)/IĪ³(2+ā†’0+) ratio of Ga84 and the P2n/P1n ratio. These results show the necessity of detailed understanding of the decay scheme, including data from neutron spectroscopy, in addition to Ī³ measurements of the multineutron emitters
    corecore